Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region

被引:51
作者
Asia Pacific Cohort Studies Collaboration
机构
[1] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2050, Australia
基金
英国医学研究理事会;
关键词
Asia-Pacific; cardiovascular diseases; cardiovascular risk; cholesterol; coronary heart disease; diabetes mellitus; lipids; stroke;
D O I
10.1007/s00125-007-0801-2
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Aims/hypothesis The aim of this study was to assess the association between total cholesterol and major cardiovascular diseases among persons with and without diabetes in the Asia-Pacific region. Methods We used data on individual participants in 30 cohort studies from the Asia-Pacific region to compute the hazards ratios and 95% CIs for participants with and without diabetes at baseline, using Cox proportional models. Analyses were stratified by sex and region (Asia vs Australia or New Zealand) and adjusted for age. Repeat measurements of total cholesterol were used to adjust for regression dilution bias. Results The analysis included 333,533 individuals (6.3% with diabetes at baseline) who experienced 6,074 fatal and non-fatal cardiovascular events over a median follow-up period of 4.0 years. Total cholesterol was positively associated with coronary heart disease (CHD) and ischaemic stroke, and negatively with haemorrhagic stroke in a continuous, log-linear fashion, similarly among participants with and without diabetes. Each 1 mmol/l increase above the 'usual' level for total cholesterol was associated with a 41% (95% CI 23-63%) and 42% (95% CI 35-50%) greater risk of CHD among participants with and without diabetes. The corresponding values for ischaemic stroke were 23% (95% CI 0-52%) and 31% (95% CI 20-44%), respectively. These results were broadly consistent for sex, age and region. Conclusions/interpretation Total cholesterol is associated with similarly increased risks of cardiovascular events in people with and without diabetes. While abnormal levels of other lipid fractions are frequently observed in people with diabetes, these data support aggressive lowering of total cholesterol and LDL-cholesterol levels for prevention of cardiovascular events.
引用
收藏
页码:2289 / 2297
页数:9
相关论文
共 28 条
[1]
Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men - A general population study [J].
Adlerberth, AM ;
Rosengren, A ;
Wilhelmsen, L .
DIABETES CARE, 1998, 21 (04) :539-545
[2]
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[3]
2-S
[4]
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[5]
*AS PAC COH STUD C, 1999, CVD PREVENTION, V0002
[6]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[7]
RISK-FACTORS FOR EARLY DEATH IN NON-INSULIN-DEPENDENT DIABETES AND MEN WITH KNOWN GLUCOSE-TOLERANCE STATUS [J].
BALKAU, B ;
ESCHWEGE, E ;
PAPOZ, L ;
RICHARD, JL ;
CLAUDE, JR ;
WARNET, JM ;
DUCIMETIERE, P .
BRITISH MEDICAL JOURNAL, 1993, 307 (6899) :295-299
[8]
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[9]
Collins R, 2003, LANCET, V361, P2005
[10]
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials [J].
Costa, Joao ;
Borges, Margarida ;
David, Claudio ;
Carneiro, Antnio Vaz .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7550) :1115-1118C